Trial Profile
Real-World Outcome of Psoriasis Patients in Korea on Adalimumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Apr 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- Acronyms RAPSODI
- Sponsors AbbVie
- 12 Apr 2019 Status changed from active, no longer recruiting to completed.
- 23 Oct 2018 Planned End Date changed from 1 Nov 2018 to 25 Mar 2019.
- 23 Oct 2018 Planned primary completion date changed from 1 Nov 2018 to 25 Mar 2019.